Final Day of JP Morgan Conference: Affymetrix, Celera, Cepheid, Complete Genomics, RainDance | GenomeWeb

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – On the final day of the JP Morgan Healthcare Conference, several molecular tools and diagnostics vendors revealed their plans for 2011.

Among the firms that presented, Affymetrix talked about the firm's efforts in cytogenetics, Celera talked about its assay pipeline and search for a partner, and Complete Genomics said it is about to introduce a new technology that will make its sequencing more accurate while lowering cost.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.